Enveric Biosciences, a forward-thinking biotechnology company specializing in neuroplastogenic treatments for neuropsychiatric disorders, has announced preclinical results that underscore the potential of their novel drug candidate, EB-003. These findings, detailed…
Psychedelics biotech Enveric Biosciences announced positive preclinical results of its EB-003 drug candidate to be delivered via oral administration. EB-003 is a new, neuroplastogenic molecule designed to treat serious mental…
Biotechnology company Enveric Biosciences (NASDAQ: ENVB) said it is prioritizing the development of EB-003, a compound designed to treat mental health disorders without hallucinogenic effects. The company said EB-003 is intended…
This past week, an FDA advisory committee voted 9-2 to reject the validity of therapy-assisted MDMA clinical trials conducted by Lykos Therapeutics for the treatment of PTSD. The FDA does…
A day after a panel of advisers to the Food and Drug Administration expressed deep concerns about the use of MDMA to help treat post-traumatic stress disorder, companies working to…
Enveric Biosciences announced it has signed a nonbinding term sheet to out-license a class of novel psilocin prodrugs to MindBio Therapeutics, an agreement that could yield more than $66 million…
Enveric Biosciences signed a non-binding term sheet to out-license a class of novel psilocin products to MinBio Therapeutics for up to $66.5 million in milestone payments. Full Article >>
Enveric Biosciences reported it financial results on Wednesday for the first quarter of 2024 ended March 31, 2024. “We believe the first quarter of 2024 was a highly productive period…
Psychedelics started 2024 with a bang, and the innovative medicines are continuing to gain traction as the year progresses. This week saw one of the globe’s top five biggest pharmaceutical…
On the heels of its announced partnership with MindBio (CNSX: MBIO) this week, Enveric Biosciences (NASDAQ: ENVB) said that it is trying to nail down potential licensing contracts for more…